News stories about Teligent (NASDAQ:TLGT) have been trending positive on Monday, Accern Sentiment reports. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Teligent earned a daily sentiment score of 0.26 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.7421115972765 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Teligent (NASDAQ:TLGT) traded down $0.06 during mid-day trading on Monday, reaching $2.94. The company’s stock had a trading volume of 300,600 shares, compared to its average volume of 510,116. The company has a quick ratio of 2.71, a current ratio of 3.28 and a debt-to-equity ratio of 2.23. The stock has a market cap of $157.53, a price-to-earnings ratio of -13.36, a PEG ratio of 58.80 and a beta of 1.07. Teligent has a 1-year low of $2.75 and a 1-year high of $9.54.
A number of research analysts have weighed in on the company. TheStreet lowered Teligent from a “c-” rating to a “d+” rating in a report on Wednesday, November 1st. Canaccord Genuity lowered Teligent from a “buy” rating to a “hold” rating and reduced their target price for the company from $9.00 to $5.00 in a report on Tuesday, November 7th. Finally, Zacks Investment Research lowered Teligent from a “hold” rating to a “strong sell” rating in a report on Saturday, November 11th. Three analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $7.00.
ILLEGAL ACTIVITY NOTICE: “Teligent (TLGT) Earns Media Impact Score of 0.26” was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.thelincolnianonline.com/2018/02/12/teligent-tlgt-earns-media-impact-score-of-0-26.html.
Teligent Company Profile
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.